Literature DB >> 3488191

Therapy of acute otitis media caused by Branhamella catarrhalis. Preliminary report.

P A Shurin, G F Van Hare.   

Abstract

Since 1980, we have observed an increased incidence of otitis media caused by Branhamella catarrhalis. The outcome of therapy of acute otitis media caused by this organism has been studied in a number of randomised clinical trials. 75% of isolates produced beta-lactamase. Failure to sterilise B. catarrhalis-infected middle ear exudates occurred in 3 of 11 patients treated with amoxycillin or bacampicillin, 2 of 19 treated with cefaclor, but in no patients treated with co-trimoxazole (n = 10) or amoxycillin-clavulanic acid (Augmentin), [n = 9]. All treatment failures were associated with beta-lactamase-producing strains of B. catarrhalis. The emergence of antibiotic-resistant strains of B. catarrhalis in acute otitis media indicates the need for a re-evaluation of initial antibiotic therapy of this infection. This may be particularly true for areas where there is a high incidence of strains which elaborate beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488191     DOI: 10.2165/00003495-198600313-00027

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  10 in total

1.  beta-Lactamase-producing Branhamella catarrhalis causing otitis media in children.

Authors:  A L Kovatch; E R Wald; R H Michaels
Journal:  J Pediatr       Date:  1983-02       Impact factor: 4.406

2.  In vitro sensitivity to penicillin V and beta-lactamase production of Branhamella catarrhalis.

Authors:  B E Malmvall; J E Brorsson; J Johnsson
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

3.  Branhamella (Neisseria) catarrhalis--a lower respiratory tract pathogen?

Authors:  M A Johnson; W L Drew; M Roberts
Journal:  J Clin Microbiol       Date:  1981-06       Impact factor: 5.948

4.  A randomized controlled trial of cefaclor compared with trimethoprim-sulfamethoxazole for treatment of acute otitis media.

Authors:  C D Marchant; P A Shurin; V A Turcyzk; J C Feinstein; C E Johnson; D E Wasikowski; L J Knapp; M A Tutihasi
Journal:  J Pediatr       Date:  1984-10       Impact factor: 4.406

5.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

6.  Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections.

Authors:  N J Slevin; J Aitken; P E Thornley
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

7.  Influence of beta-lactamase-producing strains of Branhamella catarrhalis and Haemophilus influenzae on certain beta-lactam antibiotics.

Authors:  J Johnsson; J E Brorson
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

8.  Emergence of beta-lactamase-producing strains of Branhamella catarrhalis as important agents of acute otitis media.

Authors:  P A Shurin; C D Marchant; C H Kim; G F Van Hare; C E Johnson; M A Tutihasi; L J Knapp
Journal:  Pediatr Infect Dis       Date:  1983 Jan-Feb

9.  Preliminary serologic evidence for a pathogenic role of Branhamella catarrhalis.

Authors:  M Leinonen; J Luotonen; E Herva; K Valkonen; P H Mäkelä
Journal:  J Infect Dis       Date:  1981-12       Impact factor: 5.226

10.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

  10 in total
  1 in total

1.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.